Recommendations on testing for thrombophilia in venous thromboembolic disease: A french consensus guideline

Journal des Maladies Vasculaires

Volumn 34, Issue 3, 2009, Pages 156-203

  Pernod, G ^a   Biron Andreani, C ^b   Morange, P E ^c   Boehlen, F ^d   Constans, J ^e   Couturaud, F ^f   Drouet, L ^g   Jude, B ^h   Lecompte, T ⁱ   Le Gal, G ^f   Trillot, N ^h   Wahl, D ⁱ  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

^g HÔPITAL LARIBOISIÈRE   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8;

AGE; ARTICLE; COHORT ANALYSIS; CONSENSUS; FEMALE; FRANCE; GENETIC POLYMORPHISM; GENETICS; HUMAN; HYPERHOMOCYSTEINEMIA; MEDLINE; META ANALYSIS; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREGNANCY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

AGE FACTORS; ANTITHROMBINS; COHORT STUDIES; CONSENSUS; FACTOR V; FACTOR VIII; FEMALE; FRANCE; HUMANS; HYPERHOMOCYSTEINEMIA; MEDLINE; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; PREGNANCY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 70149120091     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmv.2009.02.005     Document Type: Article

References (146)

1. Grody WA, Griffi n JH, Taylor AK, Korf BR, Heit JA, ACMG Factor V Leiden Working Group. American College of Medical Genetics Consensus. Statement on factor V Leiden mutation. Testing. Genet Med 2001;3:139-48.
2. Olson JD. College of American Pathologists Consensus Conference XXXVI: Diagnostic. Issues in thrombophilia. Arch Pathol Lab Med. 2002;126:1277-80.
3. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002;126:1304-8.
4. Emmerich J. A qui faire un bilan de thrombophilie et lequel ? Rev Prat 2007;57:711-23.
5. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
6. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital defi ciency of antithrombin III, protein C, protein S. Thromb Haemost 1994;72:352-8.
7. Coppens M, van Mourik JA, Eckmann CM, Buller HR, Middeldorp S. Current practise of testing for inherited thrombophilia. J Thromb Haemost 2007;5:1979-81.
8. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest 2008;133(Suppl. 6):454S-545.
9. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol 2008;143:321-35.
10. Brouwer JLP, Veeger NJGM, Kluin-Nelemans C, van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 2006;145:807-15.
11. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997;78:631-5.
12. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004; 140:330-7.
13. Sanson BJ, Simioni P, Tormene D, Moia M, Friederich PW, Huisman MV, et al. The incidence of venous thromboembolism in asymptomatic carriers of a defi ciency of antithrombin, protein C or protein S: a prospective cohort study. Blood 1999;94:3702-6.
14. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJ, Pabinger I, et al. Risk of a fi rst venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005;3:459-64.
15. Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997;89:1963-7.
16. Heijmans BT, Westendorp RG, Knook DL, Kluft C, Slagboom PE. The risk of mortality and the factor V Leiden mutation in a population-based cohort. Thromb Haemost 1998;80:607-9.
17. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2.
18. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007;167:935-43.
19. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a fi rst episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7.
20. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-9.
21. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87: 7-12.
22. Prandoni P, Lensing AWA, Prins MH, Bernardi E, Marchiori A, Bagatella P, et al. Residual venous thrombosis as a predictive factor of recurrent venous thrombosis. Ann Intern Med 2002;137:955-60.
23. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-6.
24. Schulman S, Riiedin AN, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
25. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313-8.
26. Vossen CY, Walker ID, Svensson P, Souto JC, Scharrer I, Preston FE, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005;25:1992-7.
27. Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F. Selective screening for the factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 1997;78:1480-3.
28. Hron G, Eichinger S, Weltermann A, Minar E, Bialonczyk C, Hirschl M, et al. Family history for venous thromboembolism and the risk for recurrence. Am J Med 2006;119:50-3.
29. van Sluis GL, Sohne M, El Kheir DY, Tanck MW, Gerdes VE, Buller HR. Family history and inherited thrombophilia. J Thromb Haemost 2006;4:2182-7.
30. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
31. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defi ned urban population. J Intern Med 1992;232:155-60.
32. Oger E. Incidence of venous thromboembolism: a communitybased study in Western France. EPI-GETBP Study Group. Groupe d'etude de la thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-60.
33. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism aetiology. Am J Med 2004;117:19-25.
34. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9.
35. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, Melton LJ 3rd.The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452-63.
36. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year populationbased study. Arch Intern Med 1998;158:585-93.
37. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8.
38. Couturaud F, Kearon C, Leroyer C, Mercier B, Abgrall JF, Le Gal G, et al. Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost 2006;96:744-9.
39. Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the fi rst episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006;4:734-42.
40. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
41. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specifi c incidence rates of venous thromboembolism among heterozygous carriers of FV Leiden mutation. Ann Intern Med 1997;126:528-31.
42. Coppens M, Reijnders JH, Middeldorp S, Doggen CJ, Rosendaal FR. Testing for inherited thrombophilia does not reduce recurrence of venous thrombosis. J Thromb Haemost 2008;6:1474-7.
43. Piette JC, Cacoub P. Antiphospholipid syndrome in the elderly: caution. Circulation 1998;97:2195-6.
44. Cohn D, Vansenne F, de Borgie C, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev 2009;21:CD007069
45. Cohn DM, Middeldorp S. Early termination of the multicentre randomised clinical trial to evaluate the benefi t of testing for thrombophilia following a fi rst venous thromboembolism: the NOSTRADAMUS study. Ned Tijdschr Geneeskd 2008;152:2093-4.
46. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, et al. Long term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-34.
47. Eichinger S, Pabinger I, Stumpfl en A, Hirschl M, Bialonczyk C, Schneider B, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997;77:624-8.
48. van Den Belt AG, Sanson BJ, Simioni P, Prandoni P, Buller HR, Girolami A, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997;157:2227-32.
49. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336: 399-403.
50. Margaglione M, Brancaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaccone L, et al. Increased risk for venous thrombosis in carriers of the prothrombin GA20210 gene variant. Ann Intern Med 1998;129:89-93.
51. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-6.
52. De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan A, Leone G. The risk of recurrent venous thromboembolism in patients with inherited defi ciency of natural anticoagulants antithrombin, protein C and protein S. Haematologica 2006;91:695-8.
53. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999;81:684-9.
54. Simioni P, Prandoni P, Lensing AW, Manfrin D, Tormene D, Gavasso S, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a fi rst episode of deep-vein thrombosis. Blood 2000;96:3329-33.
55. Miles JS, Miletich JP, Goldhaber SZ, Hennekens CH, Ridker PM. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001;37:215-8.
56. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent thrombo-embolism. N Engl J Med 2003;349:631-9.
57. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2351-61.
58. Santamaria MG, Agnelli G, Taliani MR, Prandoni P, Moia M, Bazzan M, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 2005;116:301-6.
59. Garcia-Fuster MJ, Forner MJ, Fernandez C, Gil J, Vaya A, Maldonado L. Long-term prospective study of recurrent venous thromboembolism in patients younger than 50 years. Pathophysiol Haemost Thromb 2005;34:6-12.
60. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006;166:729-36.
61. Wahlander K, Eriksson H, Lundstrom T, Billing Clason S, Wall U, et al. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. Br J Haematol 2006;133:68-77.
62. Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999;81:14-7.
63. Schulman S, Ogren M. New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb Haemost 2006;96:258-66.
64. Brouwer JLP, Lifering WM, Kate MKT, Kluin-Nelemans HC, Veeger NJGM, van der Meer J. High long term absolute risk of recurrent venous thromboembolism in patients with hereditary defi ciencies of protein S, protein C or antithrombin. J Thromb Haemost 2009;101:93-9.
65. Dentali F, Gianni M. VTE recurrence in patients with inherited defi ciencies of natural anticoagulant. J Thromb Haemost 2009, 101:5-6.
66. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5-9.
67. Tirado I, Mateo J, Soria JM, Oliver A, Martinez-Sanchez E, Vallve C, et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005;93:468-74.
68. Kyrle P, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Eng J Med 2000;343:457-62.
69. Cristina L, Benilde C, Michela C, Mirella F, Giuliana G, Gualtiero P. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004;24:504-10.
70. Cosmi B, Legnani C, Cini M, Favaretto E, Palareti G. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a fi rst idiopathic deep vein thrombosis. Thromb Res 2008;122:610-7.
71. Yap S. Classical homocystinuria: vascular risk and its prevention. J Inherit Metab Dis 2003;26:259-65.
72. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
73. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a metaanalysis. Thromb Haemost 1998;80:874-7.
74. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005 3:292-9.
75. Naess IA, Christiansen SC, Romundstad PR, Cannegieter SC, Blom HJ, Rosendaal FR, et al. Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population - results from the HUNT 2 study. Br J Haematol 2008;141:529-35.
76. Eichinger S, Stumpfl en A, Hirschl M, Bialonczyk C, Herkner K, Stain M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-9.
77. Eichinger S. Homocysteine, vitamin B6 and the risk of recurrent venous thromboembolism. Pathophysiol Haemost Thromb 2003/2004;33:342-4.
78. den Heijer M, Willems HP, Blom HJ, Gerrits WBJ, Cattaneo M, Eichinger S, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 2007;109:139-44.
79. Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E, Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med 2007;146:761-7.
80. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the fi rst thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
81. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
82. Krnic-Barrie S, Riester O'Connor C, Looney SW, Pierangeli S, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Arch Intern Med 1997;157:2101-8.
83. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998;104:332-8.
84. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the anti-phospholipid antibody syndrome. N Engl J Med 2003;349:1133-8.
85. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-53.
86. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
87. Pelissier C, Basdevant A, Conard J, Egloff M, Husson T, Guyenne TT. Progestogen contraception using chlormadinone acetate in women presenting high vascular risk. (A gynecoendocrine, metabolic and vascular study) Contracept Fertil Sex 1987;15:45-54.
88. Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004;70:437-41.
89. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7.
90. Hoibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomized, doubleblind, clinical trial. Thromb Haemost 2001;85:775-81.
91. Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000;343:1439-44.
92. Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005;3:949-54.
93. De Stefano V, Martinelli I, Rossi E, Battaglioti T, Za T, Mannuccio Mannucci P, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006;135:386-91.
94. Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ, British Society for Haematology Obstetric Haematology Group. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol 2007;139:545-58.
95. Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J, et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007;197:457.e1-21.
96. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J, American College of Chest Physicians Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest 2008;133 (Suppl. 6):844S-86.
97. SFAR 2005. Prevention de la maladie thromboembolique veineuse perioperatoire et obstetricale. Recommandations pour la pratique clinique (RPC) 2005: http://www.sfar.org/ s/IMG/pdf/preventionmte_rpc.pdf.
98. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest 2008;133(Suppl. 6):381S-453.
99. Lindahl TL, Lundahl TH, Nilsson L, Andersson CA. APCresistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee - a prospective study. Thromb Haemost 1999;81:18-21.
100. Bowler DJ, Bale E, O'Byrne J. Factor V Leiden: prevalence and thromboembolic complications after total hip replacement in Ireland. Ir J Med Sci 2007;176:273-7.
101. Engesser L, Broekmans AW, Briet E, Brommer EJ, Bertina RM. Hereditary protein S defi ciency: clinical manifestations. Ann Intern Med 1987;106:677-82.
102. Pabinger I, Schneider M. Hereditary defi cit in antithrombin III, protein C, or protein S defi ciency. A cooperative, retrospective study. Gesellschaft fur Thrombose und Hamostasefroschung (GTH) Study Group in Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996;16:742-8.
103. Hanson JN, Ascher E, DePippo P, Lorensen E, Scheinman M, Yorkovich W, et al. Saphenous vein thrombophlebitis (SVT): a deceptively benign disease. J Vasc Surg 1998;27:677-80.
104. De Moerloose P, Wutschert R, Heinzmann M, Perneger T, Reber G, Bounameaux H. Superfi cial vein thrombosis of the lower limb: infl uence of factor V Leiden, factor II G20210A and overweight. Thromb Haemost 1998;80:239-41.
105. Martinelli I, Cattaneo M, Taioli E, De Stefano V, Chiusolo, Manucci PM. Genetic risk factors for superfi cial vein thrombosis. Thromb Haemost 1999;82:1215-7.
106. De Godoy JM, Bataglia F, Braile M. Superfi cial thrombophlebitis and anticardiolipin antibodies - report of association. Angiology 2001;52:127-9.
107. De Godoy JM, Braile DM. Protein S defi ciency in repetitive superfi cial thrombophlebitis. Clin Appl Thromb Haemost 2003;9:61-2.
108. Schonauer V, Kyrle PA, Weltermann A, Minar E, Bialonczyk C, Hirschl M, et al. Superfi cial thrombophlebitis and risk for recurrent venous thromboembolism. J Vasc Surg 2003;37: 834-38.
109. Caprini JA, Goldshtein S, Glase CJ, Kataway H. Thrombophilia testing in patients with venous thrombosis. Eur J Vasc Endovasc Surg 2005;30:550-5.
110. Martinelli I, Battaglioli T, Razzari C, Manucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost 2007;5:98-101.
111. Huisman MV, Klok FA, Karami Djurabi R, Tormene D, Simioni P, Prandoni P. Factor V Leiden is associated with more distal location of deep vein thrombosis of the leg. J Thromb Haemost. 2008;6:544-5.
112. Righini M, Paris S, Le Gal G, Laroche JP, Perrier A, Bounameaux H. Clinical relevance of distal vein thrombosis. Thromb Haemost 2006;95:56-64.
113. Lensen R, Rosendaal F, Vandenbroucke J, Bertina R. Factor V Leiden: the venous thrombotic risk in thrombophilic families. Br J Haematol 2000;110:939-45.
114. Morange PE, Aillaud MF, Frere C, Brunet D, Barthet MC, Morange S, et al. Risk of a first venous or arterial event in carriers of a familial thrombophilic defect. XXI Congress International Society of Thrombosis and Haemostasis, Geneva, July 2007 [abstr O-T-008].
115. Couturaud F, Leroyer C, Julian J, Kahn S, Ginsberg J, Wells P, et al. Risk of venous thromboembolism in fi rst degree relatives of patients with unprovoked VTE who do not have factor V Leiden or the G20210A prothrombin gene mutation. XXI Congress International Society of Thrombosis and Haemostasis, Geneva, July 2007 [abstr O-T-010].
116. Lensen RP, Bertina RM, de Ronde H, Vandenbroucke JP, Rosendaal FR. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000;83:817-21.
117. Middeldorp S, Henkens CM, Koopman MM, van Pampus EC, Hamulyak K, van der Meer J, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128:15-20.
118. Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyak K, van Der Meer J, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001;135:322-7.
119. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81:198-202.
120. Simioni P, Tormene D, Prandoni P, Zerbinati P, Gavasso S, Cefalo P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002;99:1938-42.
121. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000;111:1223-9.
122. Sie P. Bilan biologique de la thrombose veineuse: quelles conditions et quel cout ? Sang Thromb Vaiss 2006;18:523-8.
123. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The thrombosis: risk and economic assessment of thrombophilia screening (TREATS) study. Health Technol Assess 2006;10: 1-110.
124. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999,72:646-51.
125. Heit JA, Sobell JL, Li H, Sommer SS. The incidence of venous thromboembolism among factor V Leiden carriers: a community-based cohort study. J Thromb Haemost 2005;3:305-11.
126. van Vlijmen EF, Brouwer JL, Veeger NJ, Eskes TK, de Graeff PA, van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007;167:282-9.
127. Couturaud F, Leroyer C, Mottier D, groupe d'etude de la thrombose de Bretagne Occidentale (GETBO). Risk factors and clinical presentation of venous thromboembolism according to the age of relatives of patients with factor V Leiden. Thromb Haemost 2008;99:793-4.
128. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-defi ciency taking oral contraceptive medication. The GTH Study Group on natural inhibitors. Thromb Haemost 1994;71:548-52.
129. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000;160:49-52.
130. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32.
131. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-500.
132. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5.
133. Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-defi cient women: implications for prophylaxis. Ann Intern Med 1996;125: 955-60.
134. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;78:1183-8.
135. Pabinger I, Nemes L, Rintelen C, Koder S, Lechler E, Loreth RM, et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 2000;1:37-41.
136. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001;86:800-3.
137. Middeldorp S, Libourel EJ, Hamulyak K, van der Meer J, Buller HR. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001;113:553-5.
138. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132:171-96.
139. Simioni P. Who should be tested for thrombophilia? Curr Opin Hematol 2006;13:337-343.
140. Bucciarelli P, Rosendaal FR, Tripodi A, Mannucci PM, De Stefano V, Palareti G, et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S defi ciency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999;19:1026-33.
141. van Boven HH, Vandenbroucke JP, Briet E, Rosendaal FR. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin defi ciency. Blood 1999;94:2590-4.
142. Folkeringa N, Brouwer JL, Korteweg FJ, Veeger NJ, Erwich JJ, van der Meer J. High risk of pregnancy-related venous thromboembolism in women with multiple thrombophilic defects. Br J Haematol 2007;138:110-6.
143. Bank I, Libourel EJ, Middeldorp S, van Pampus ECM, Koopman MMW, Hamulyak K, et al. Prothrombin 20210Amutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004; 164:1932-7.
144. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008;6:632-7.
145. Martinelli I, Battaglioli T, De Stefano V, Tormene D, Valdre L, Grandone E, et al. The risk of fi rst venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. J Thromb Haemost 2008;6:494-8.
146. Pernod G, Jouk PS, Bosson JL, Carpentier PH, Polack B. More on: asymptomatic thrombophilia - a family affair. J Thromb Haemost 2005;3:1329-30.